Based on the Arrowhead Pharmaceuticals Inc stock forecast from 8 analysts, the average analyst target price for Arrowhead Pharmaceuticals Inc is USD 54.35 over the next 12 months. Arrowhead Pharmaceuticals Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Arrowhead Pharmaceuticals Inc is Slightly Bearish, which is based on 3 positive signals and 6 negative signals. At the last closing, Arrowhead Pharmaceuticals Inc’s stock price was USD 18.54. Arrowhead Pharmaceuticals Inc’s stock price has changed by -0.16% over the past week, -6.93% over the past month and -35.98% over the last year.
No recent analyst target price found for Arrowhead Pharmaceuticals Inc
No recent average analyst rating found for Arrowhead Pharmaceuticals Inc
Company Overview Arrowhead Pharmaceuticals Inc
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California. Address: 177 East Colorado Boulevard, Pasadena, CA, United States, 91105 Read Less
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and ch...Read More
Frequently Asked Questions About Arrowhead Pharmaceuticals Inc (ARWR) Stock
Based on ratings from 8 analysts Arrowhead Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 14 buy, sell and 3 hold ratings.
Unfortunately we do not have enough data on ARWR's stock to indicate if its a good dividend stock.
Based on targets from 8 analysts, the average taret price for ARWR is USD 54.35 over the next 12 months. The maximum analyst target price is USD 90 while the minimum anlayst target price is USD 27.
ARWR stock's Price/Earning ratio is 478.56.
Our analysis grades ARWR stock's Price / Earning ratio at F. This means that ARWR stock's Price/Earning ratio is above 97% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this ARWR may be a overvalued for its sector.
The last closing price of ARWR's stock was USD 18.54.
The most recent market capitalization for ARWR is USD 2.30B.
Based on targets from 8 analysts, the average taret price for ARWR is projected at USD 54.35 over the next 12 months.
This means that ARWR's stock price may go up by +193.17% over the next 12 months.
We can't find any ETFs which contains Arrowhead Pharmaceuticals Inc's stock.
As per our most recent records Arrowhead Pharmaceuticals Inc has 525 Employees.
Arrowhead Pharmaceuticals Inc's registered address is 177 East Colorado Boulevard, Pasadena, CA, United States, 91105.
You can get more information about it from Arrowhead Pharmaceuticals Inc's website at https://arrowheadpharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Arrowhead Pharmaceuticals Inc (ARWR) Stock
Based on ratings from 8 analysts Arrowhead Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 14 buy, sell and 3 hold ratings.
Unfortunately we do not have enough data on ARWR's stock to indicate if its a good dividend stock.
Based on targets from 8 analysts, the average taret price for ARWR is USD 54.35 over the next 12 months. The maximum analyst target price is USD 90 while the minimum anlayst target price is USD 27.
ARWR stock's Price/Earning ratio is 478.56.
Our analysis grades ARWR stock's Price / Earning ratio at F. This means that ARWR stock's Price/Earning ratio is above 97% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this ARWR may be a overvalued for its sector.
The last closing price of ARWR's stock was USD 18.54.
The most recent market capitalization for ARWR is USD 2.30B.
Based on targets from 8 analysts, the average taret price for ARWR is projected at USD 54.35 over the next 12 months.
This means that ARWR's stock price may go up by +193.17% over the next 12 months.
We can't find any ETFs which contains Arrowhead Pharmaceuticals Inc's stock.
As per our most recent records Arrowhead Pharmaceuticals Inc has 525 Employees.
Arrowhead Pharmaceuticals Inc's registered address is 177 East Colorado Boulevard, Pasadena, CA, United States, 91105.
You can get more information about it from Arrowhead Pharmaceuticals Inc's website at https://arrowheadpharma.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ARWR !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
